Medical technology company, Surgalign (NASDAQ:SRGA) stock price slumps 42% on Tuesday pre-market hours as the company filed for bankruptcy with estimated assets and liabilities in the range of $50M-$100M.
The company announced a 20% workforce reduction in March, and in November last year, the company approved a corporate restructuring plan, that included discontinuing some of its lower-performing units.